Aclidinium bromide

Drug Profile

Aclidinium bromide

Alternative Names: Aclinidinium; Bretaris Genuair; Eklira Genuair; KRP-AB1102; LAS-34273; Tudorza Pressair; TudorzaGenuair

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Allergan; Almirall S.A.; AstraZeneca; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 17 Mar 2017 AstraZeneca and Circassia Pharmaceuticals agree to co-promote and co-develop aclidinium bromide in USA for chronic obstructive pulmonary disease
  • 13 Jan 2017 AstraZeneca and Parexel plan the phase III AVANT trial for Chronic obstructive pulmonary disease in India, Philippines, Taiwan and Vietnam (NCT03022097)
  • 13 Jan 2017 AstraZeneca and Parexel withdrew the phase III AVANT trial, prior to recruitment, for Chronic obstructive pulmonary disease in China (NCT03022097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top